Volume | 70,402 |
|
|||||
News | - | ||||||
Day High | 3.30 | Low High |
|||||
Day Low | 3.13 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aileron Therapeutics Inc | ALRN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.29 | 3.13 | 3.30 | 3.24 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
945 | 70,402 | $ 3.27 | $ 230,065 | - | 1.01 - 7.42 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:50:25 | 3 | $ 3.21 | USD |
Aileron Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
15.88M | 4.89M | - | 0 | -15.73M | -3.22 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aileron Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALRN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.15 | 3.30 | 3.02 | 3.23 | 20,906 | 0.09 | 2.86% |
1 Month | 3.81 | 4.00 | 3.02 | 3.54 | 34,004 | -0.57 | -14.96% |
3 Months | 5.55 | 7.42 | 3.02 | 4.70 | 99,227 | -2.31 | -41.62% |
6 Months | 2.24 | 7.42 | 2.15 | 4.58 | 98,254 | 1.00 | 44.64% |
1 Year | 1.83 | 7.42 | 1.01 | 3.77 | 67,365 | 1.41 | 77.05% |
3 Years | 28.00 | 28.00 | 1.01 | 10.14 | 302,890 | -24.76 | -88.43% |
5 Years | 18.00 | 49.40 | 1.01 | 22.77 | 626,704 | -14.76 | -82.00% |
Aileron Therapeutics Description
Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. |